- Design
- Prospective cohort (ARIC Neurocognitive Study)
- Population
- 1,515 adults with plasma samples at mean age 59 and 77
- Primary outcome
- Change in memory, language, executive and global cognition over 11 years
- Effect
- Midlife p-tau181 and memory: β −0.030 SD (95% CI −0.059 to −0.001)
This analysis of the US ARIC cohort measured plasma Aβ42/40, p-tau181, neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in stored midlife samples (mean age 59) and late-life samples (mean age 77) from 1,515 people, then tracked cognition over 11 years.
Only midlife p-tau181 was associated with later memory decline, and the effect was small (β −0.030 SD per SD of p-tau181, CI −0.059 to −0.001). In late life, p-tau181, NfL and GFAP were each associated with faster decline, most strongly in memory (p-tau181 β −0.091).
The finding supports a long preclinical phase in Alzheimer disease. It does not support testing cognitively normal middle-aged people: the midlife association was weak and no intervention is known to change it.
- Do not order Alzheimer blood biomarkers in cognitively normal middle-aged patients.
- In older patients with cognitive symptoms, p-tau181 is the marker most linked to memory decline.
- Raised NfL and GFAP are non-specific and need clinical context.
- Counsel patients that a biomarker result is a risk signal, not a diagnosis.
Why it matters
Biology appears decades before symptoms, but that does not yet make midlife testing useful.
Don't overread it
An association in midlife does not make p-tau181 a screening test for healthy adults.
The statistics, in plain English
β −0.030 SD means each standard-deviation rise in p-tau181 was linked to slightly faster memory decline. The interval only just excludes zero, so the effect is real but small. This is observational, and stored samples measured decades later can drift.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free